secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2024-01-19T23:59:59+00:00
Accession:  0001437749-24-001757
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart receives $9.27M BARDA award for Phase 2b COVID pill vaccine; Nasdaq extends bid price compliance to July 2024
--------------------------------------------------------------------------------

- Vaxart awarded $9.27M from BARDA Project NextGen to prepare for a 10,000-subject Phase 2b study of its oral XBB COVID-19 vaccine vs. an approved mRNA comparator.
- Project NextGen is a $5B HHS initiative to develop innovative COVID vaccines and therapeutics providing broader, more durable protection.
- Nasdaq granted an additional 180-day compliance period until July 15, 2024 to meet the $1.00 minimum bid price requirement.
- Vaxart is considering options, including a reverse stock split, to regain compliance; no assurance of success is given.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774924001757/0001437749-24-001757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774924001757/vxrt20240119_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-001757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer